Last updated on March 2019

A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough

Brief description of study

The purpose of this study is to determine the effectiveness of three doses of orvepitant, taken once a day, in the treatment of chronic refractory cough.

Detailed Study Description

A multi-center, double-blind, randomized, parallel group, placebo-controlled dose range study in subjects with chronic refractory cough (CRC).

Doses of orvepitant (10 mg/day, 20 mg/day and 30 mg/day) and placebo will be investigated in four parallel groups.

Each group will compromise of approximately 61 subjects, randomized 1:1:1:1 (approximately 244 subjects in total).

All subjects will enter a three-week screening period to determine eligibility. Eligible subjects will be randomized at the Baseline/Day 1 visit and enter a 12-week double-blind dosing period. During this period there will be four visits at Weeks 2, 4, 8 and 12. There will be a final safety follow-up visit at Week 14.

Clinical Study Identifier: NCT02993822

Contact Investigators or Research Sites near you

Start Over

Principal Investigator

Study Site 31
North Shields, United Kingdom

Principal Investigator

Study Site 47
Newcastle Upon Tyne, United Kingdom

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.